This content is Free Access.
25,593 Views
•
16:57 min
•
February 14, 2012
DOI:
Summary
Automatically generated
Dopamine replacement pharmacotherapy using L-DOPA is the most commonly used symptomatic treatment of Parkinson’s disease, but is accompanied by side effects including involuntary abnormal movements, termed dyskinesia 1. Here, a protocol for MALDI imaging mass spectrometry is presented that detects changes in rat brain neuropeptide levels related to dyskinesia.
Explore More Videos
MALDI Imaging Mass SpectrometryNeuropeptidesParkinson’s DiseaseIMSMolecular SpeciesMALDI MatrixIntact PeptidesProteinsMass AnalyzerMALDI TOF/TOF Mass SpectrometerImaging TechniquesMolecules Of InterestUnsupervised AnalysisMolecular SpecificitySensitivityRegion-specific Distribution ProfilesAnimal Model Parkinson’s DiseaseNeurodegenerative DiseaseDopamine ReplacementL-DOPA-induced Dyskinesias (LID)Opioid Precursor Prodynorphin MRNADynorphin PeptidesNeurotransmission
Read Article
Cite this Article
Hanrieder, J., Ljungdahl, A., Andersson, M. MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease. J. Vis. Exp. (60), e3445, doi:10.3791/3445 (2012).
Copy